VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ACRSAclaris Therapeutics, Inc.
$4.84$584M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksACRSEarnings History

ACRS logoAclaris Therapeutics, Inc. (ACRS) Earnings History

Net Loss

13 years of earnings data (2013–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$70M
● Net Loss
TTM EPS (Diluted)
$-0.54
Per share, diluted
YoY EPS Growth
+69.0%
Excellent
Net Margin
-829.6%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-975.9%
Gross Margin73.3%
Return on Equity-50.2%
Return on Assets-34.1%
Record Annual Net Income-$5MFY2013
Record Quarterly EPS$-0.02Q4 2023
Consecutive Profitable Years0years
Q1 2026
Net Income-$20M
EPS (Diluted)$-0.15
YoY Growth+69.0%Excellent
QoQ Growth-0.1%Slow

Loading earnings history...

Aclaris Therapeutics, Inc. (ACRS) Earnings Overview

As of June 23, 2026, Aclaris Therapeutics, Inc. (ACRS) reported trailing twelve-month net income of -$70M, reflecting +69.0% year-over-year growth. The company earned $-0.54 per diluted share over the past four quarters, with a net profit margin of -829.6%.

Looking at the long-term picture, ACRS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2013.

Aclaris Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including NKTR (-$158M net income, -297.1% margin), PTGX (-$115M net income, -282.8% margin), DAWN (-$107M net income, -67.8% margin), ACRS has room to improve margins relative to the peer group. Compare ACRS vs NKTR →

ACRS Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ACRS logoACRSCurrent
-$70M$-0.54-829.6%-50.2%+69.0%—
NKTR logoNKTR
-$158M$-6.39-297.1%-217.9%-12.1%
PTGX logoPTGX
-$115M$-1.63-282.8%-20.2%-148.5%
DAWN logoDAWN
-$107M$-1.04-67.8%-22.7%-2.0%
RCUS logoRCUS
-$369M$-2.94-142.9%-63.3%-4.8%
DERM logoDERM
-$10M$-0.35-18.5%-44.0%+34.7%
Best in group
Lowest in group

ACRS Historical Earnings Data (2013–2025)

13 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$65M+50.8%-$76M$-0.53-829.6%-975.9%
2024-$132M-49.3%-$142M$-1.71-705.5%-758.2%
2023-$88M-1.8%-$97M$-1.27-283.1%-311.6%
2022-$87M+4.4%-$90M$-1.33-292.1%-302.0%
2021-$91M-78.1%-$90M$-1.60-1344.0%-1327.1%
2020-$51M+68.4%-$51M$-1.20-787.0%-785.4%
2019-$161M-21.6%-$111M$-3.46-3817.2%-2627.3%
2018-$133M-93.7%-$135M$-4.03-1315.4%-1341.9%
2017-$69M-42.5%-$72M$-2.44-4071.5%-4303.2%
2016-$48M-133.8%-$49M$-2.25--
2015-$21M-141.4%-$21M$-1.10--
2014-$9M-62.7%-$9M$-0.80--
2013-$5M--$5M$-3.13--

Download Data

Export ACRS earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

13+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ACRS — Frequently Asked Questions

Quick answers to the most common questions about buying ACRS stock.

What is ACRS earnings per share (EPS)?

ACRS trailing twelve-month (TTM) diluted EPS is $-0.54, reflecting +69.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.

What is Aclaris Therapeutics, Inc.'s net income?

Aclaris Therapeutics, Inc. (ACRS) trailing twelve-month net income is $-70M as of 2025. Earnings grew +69.0% year-over-year.

Is ACRS profitable?

ACRS is not currently profitable on a TTM basis, reporting a net loss of $-70M. Net margin is -829.6%. Investors should monitor for a return to profitability.

What is ACRS's earnings growth rate?

ACRS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.

What are ACRS's profit margins?

Aclaris Therapeutics, Inc. net profit margin is -829.6%, operating margin is -975.9%, and gross margin is +73.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -50.2%.

Is ACRS growing earnings?

Yes, ACRS earnings are accelerating — EPS growth of +69.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-70M. Earnings momentum is strengthening.

What was ACRS's best earnings year?

Aclaris Therapeutics, Inc.'s highest annual net income on record is $-5M, achieved in fiscal year 2013. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.

What were ACRS's earnings last quarter?

ACRS's most recent reported quarter was Q1 2026. Net income was $-20M with diluted EPS of $-0.15. For a full breakdown of all quarters, see the quarterly earnings table on this page.

ACRS Earnings Over Time (2013–2025)

Net income & EPS — annual and quarterly view